CD7-CAR-T Cells in Pediatric Relapsed/Refractory CD7+ T-ALL/LL — Stella

Clinical trial discovery in plain English. Data sourced from ClinicalTrials.gov.

About Browse conditions ClinicalTrials.gov ↗

Stella is not a medical provider and does not give medical advice. AI-generated summaries are for informational purposes only. Always consult your doctor before making any healthcare decisions.

CD7-CAR-T Cells in Pediatric Relapsed/Refractory CD7+ T-ALL/LL — Stella

Home/T-Cell Acute Lymphoblastic Leukemia/Lymphoblastic Lymphoma/

View on ClinicalTrials.gov

Recruiting

Back to T-Cell Acute Lymphoblastic Leukemia/Lymphoblastic Lymphoma trials

Phase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.

Trial locations(1 site)

Italy

Ospedale Pediatrico Bambino Gesù, Rome, Rome

Key details

Phase

Early testing / Safety & dosing

Sponsor

Bambino Gesù Hospital and Research Institute

Enrollment target

~26 participants

Started

April 2024

Primary completion

September 2028

Age range

6 Months – 25 Years

Last updated December 2025

Interested in joining?

Tell us you're interested and we'll help connect you with the research team. We'll never share your email without your permission.

Your name

Email address

Stella acts as an intermediary. Researcher contact info is never exposed.

Follow this trial

Get notified in plain English when this trial's status changes. No account required.